An Australian stem cell and regenerative medicine company

ASX Announcements

18 Jan 2021 Completion of Entitlement Offer and Shortfall Placement
11 Jan 2021 Entitlement Offer – Closing Date Reminder
31 Dec 2020 Cleansing Notice
30 Dec 2020 Appnedix 2A
30 Dec 2020 2020 Review and Outlook
29 Dec 2020 Becoming a substantial holder
24 Dec 2020 Cleansing Notice
23 Dec 2020 Appendix 2A
21 Dec 2020 Letter to Ineglible Shareholders
21 Dec 2020 Offer Booklet and Entitlement & Acceptance Form
21 Dec 2020 Cynata Entitlement Offer Opens
21 Dec 2020 Cleansing Notice
18 Dec 2020 Cynata provides update on Placement and Appendix 2A
15 Dec 2020 Letter to Optionholders
11 Dec 2020 Notice Under Section 708AA of the Corporations Act
11 Dec 2020 Investor Presentation
11 Dec 2020 Proposed Issue of Securities
11 Dec 2020 CYP Closes $15m Institutional Placement to Expand Pipeline
30 Nov 2020 Appendix 3Ys x 5
30 Nov 2020 Appendix 3G
24 Nov 2020 Replacement Constitution
24 Nov 2020 Results of Annual General Meeting
24 Nov 2020 AGM Presentations
18 Nov 2020 Cynata Technology Featured on Front Cover of Nature Medicine
11 Nov 2020 Phase 3 Osteoarthritis Clinical Trial Commences
30 Oct 2020 Quarterly Activity Report & Appendix 4C
29 Oct 2020 AusBiotech Conference Presentation
23 Oct 2020 Annual Report to Shareholders
23 Oct 2020 Letter to Shareholders, Notice of AGM & Proxy Form
06 Oct 2020 Date of AGM & Closing Date for Director Nominations
24 Sep 2020 Potential Utility of Cymerus MSCs in Heart Attack Model
15 Sep 2020 Cynata Clinical Trial Results Published in Nature Medicine
14 Sep 2020 Appendix 3G
07 Sep 2020 Cymerus MSCs Effective in Preclinical Lung Disease Study
25 Aug 2020 Appendix 4E & Annual Report
24 Aug 2020 Patient Enrolment Opens in COVID-19 Clinical Trial
19 Aug 2020 Appendix 3G
18 Aug 2020 Cynata Appoints Dr Geoff Brooke as Chairman
14 Aug 2020 Cynata Investor Presentation
07 Aug 2020 Notice of Allowance from Korean Patent Office
05 Aug 2020 Notification of Expiry of Unlisted Options
30 Jul 2020 Cynata Announces Positive Results from GvHD Trial Follow-up
28 Jul 2020 Quarterly Activity Report & Appendix 4C
20 Jul 2020 Notification of Expiry of Unlisted Options
01 Jul 2020 Securities Dealing Policy
01 Jul 2020 Final Director's Interest Notice
24 Jun 2020 Appendix 3Y-Dr Geoff Brooke
18 Jun 2020 Ethics Approval & Expedited Pathway for Phase 3 OA Trial
16 Jun 2020 Appendix 3X-Darryl Maher
16 Jun 2020 Appendix 3Y-Ross Macdonald